title: [Treatment of community-acquired pneumonia--treatment].
abstract: Penicillin is the drug of choice for treatment of community-acquired pneumonia (CAP) in Denmark. The primary determinant for therapeutic activity of penicillin is ''penicillin time'' (T>MIC), i.e. time with penicillin concentration above minimum inhibitory concentration. Eradication of S. pneumoniae requires T>MIC above 40-50%. The second determinant for therapeutic activity is the ratio between maximum penicillin concentration in serum and MIC (Cmax/MIC). Considering penicillin pharmacokinetics, intravenous penicillin 2 million units four times a day is recommended as empirical treatment of CAP.
authors.affiliation: Arhus Universitetshospital, Arhus Sygehus, Klinisk Farmakologisk Afdeling, Arhus C. ljubica.andersen@farm.au.dk
authors.forename: Ljubica Vukelic
authors.initials: LV
authors.lastname: Andersen
authors.forename: Birgitte
authors.initials: B
authors.lastname: Brock
authors.forename: Preben
authors.initials: P
authors.lastname: Jakobsen
authors.forename: Lars Peter
authors.initials: LP
authors.lastname: Nielsen
mesh_terms: D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007275:Injections, Intravenous; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects
chemical_list: D010406:Penicillins